Value of Holter monitoring in predicting long-term efficacy and inefficacy of amiodarone used alone and in combination with class 1A antiarrhythmic agents in patients with ventricular tachycardia

Soo G. Kim, S. D. Felder, I. Figura, D. R. Johnston, L. E. Waspe, John Devens Fisher

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The value of two reported and two new ambulatory electrocardiographic (Holter) criteria was studied in 80 patients taking amiodarone for refractory recurrent sustained ventricular tachycardia. In the 80 patients, the four Holter criteria were as follows: I - 85% or greater reduction of ventricular premature complexes and abolition of couplets and nonsustained ventricular tachycardia in 74 patients who had 10 or more ventricular premature complexes/h, or any couplets or nonsustained ventricular tachycardia/24 hours at baseline; II - abolition of nonsustained ventricular tachycardia in 51 patients who had nonsustained ventricular tachycardia at baseline; III - 85% or greater reduction of ventricular premature complexes and abolition of nonsustained ventricular tachycardia in 64 patients who had 30 or more ventricular premature complexes/h at baseline; and IV - 85% or greater reduction of ventricular premature complexes and abolition of nonsustained ventricular tachycardia in 73 patients who had 10 or more ventricular premature complexes/h at baseline. Amiodarone was judged effective in, respectively, 51 of 74, 44 of 51, 51 of 64, and 61 of 73 patients by criterion I, II, III or IV. During the follow-up period (19 ± 20 months), there were 19 instances of recurrences of ventricular arrhythmia or sudden death. Actuarial arrhythmia-free survival rate at 24 months was 84, 74, 86 and 85%, respectively, in patients with efficacy by criterion I, II, III or IV and 61, 43, 48 and 39%, respectively, in patients with inefficacy (p < 0.015 for all). Many patients with efficacy by Holter criteria, however, had a recurrence of arrhythmia, suggesting insensitivity of these Holter criteria. At 24 months, the respective sensitivity of criteria I, II, III and IV was 53, 29, 50 and 47%, the specificity was 86, 94, 90 and 95% and the predictive accuracy was 73, 63, 75, and 76%. Conclusions: 1) Inefficacy of amiodarone therapy by Holter criteria predicts a poor outcome but efficacy does not preclude a poor outcome (insensitivity). 2) Criterion I is the most sensitive but the least specific. 3) Criterion II could be used in only 51 of 80 patients and is the least sensitive. 4) Criterion III (with a stricter entry criterion) could be used in fewer patients than criterion I or IV and accuracy is not better. 5) Criterion IV is the most specific and has the best predictive accuracy. 6) Further studies should be done to identify the predictor of arrhythmia recurrence in patients with Holter criteria of efficacy.

Original languageEnglish (US)
Pages (from-to)169-174
Number of pages6
JournalJournal of the American College of Cardiology
Volume9
Issue number1
StatePublished - 1987

Fingerprint

Ambulatory Electrocardiography
Amiodarone
Proxy
Ventricular Tachycardia
Ventricular Premature Complexes
Cardiac Arrhythmias
Recurrence
Sudden Death

ASJC Scopus subject areas

  • Nursing(all)

Cite this

@article{0ee971f374c244f1b304d1bb19ff63ad,
title = "Value of Holter monitoring in predicting long-term efficacy and inefficacy of amiodarone used alone and in combination with class 1A antiarrhythmic agents in patients with ventricular tachycardia",
abstract = "The value of two reported and two new ambulatory electrocardiographic (Holter) criteria was studied in 80 patients taking amiodarone for refractory recurrent sustained ventricular tachycardia. In the 80 patients, the four Holter criteria were as follows: I - 85{\%} or greater reduction of ventricular premature complexes and abolition of couplets and nonsustained ventricular tachycardia in 74 patients who had 10 or more ventricular premature complexes/h, or any couplets or nonsustained ventricular tachycardia/24 hours at baseline; II - abolition of nonsustained ventricular tachycardia in 51 patients who had nonsustained ventricular tachycardia at baseline; III - 85{\%} or greater reduction of ventricular premature complexes and abolition of nonsustained ventricular tachycardia in 64 patients who had 30 or more ventricular premature complexes/h at baseline; and IV - 85{\%} or greater reduction of ventricular premature complexes and abolition of nonsustained ventricular tachycardia in 73 patients who had 10 or more ventricular premature complexes/h at baseline. Amiodarone was judged effective in, respectively, 51 of 74, 44 of 51, 51 of 64, and 61 of 73 patients by criterion I, II, III or IV. During the follow-up period (19 ± 20 months), there were 19 instances of recurrences of ventricular arrhythmia or sudden death. Actuarial arrhythmia-free survival rate at 24 months was 84, 74, 86 and 85{\%}, respectively, in patients with efficacy by criterion I, II, III or IV and 61, 43, 48 and 39{\%}, respectively, in patients with inefficacy (p < 0.015 for all). Many patients with efficacy by Holter criteria, however, had a recurrence of arrhythmia, suggesting insensitivity of these Holter criteria. At 24 months, the respective sensitivity of criteria I, II, III and IV was 53, 29, 50 and 47{\%}, the specificity was 86, 94, 90 and 95{\%} and the predictive accuracy was 73, 63, 75, and 76{\%}. Conclusions: 1) Inefficacy of amiodarone therapy by Holter criteria predicts a poor outcome but efficacy does not preclude a poor outcome (insensitivity). 2) Criterion I is the most sensitive but the least specific. 3) Criterion II could be used in only 51 of 80 patients and is the least sensitive. 4) Criterion III (with a stricter entry criterion) could be used in fewer patients than criterion I or IV and accuracy is not better. 5) Criterion IV is the most specific and has the best predictive accuracy. 6) Further studies should be done to identify the predictor of arrhythmia recurrence in patients with Holter criteria of efficacy.",
author = "Kim, {Soo G.} and Felder, {S. D.} and I. Figura and Johnston, {D. R.} and Waspe, {L. E.} and Fisher, {John Devens}",
year = "1987",
language = "English (US)",
volume = "9",
pages = "169--174",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Value of Holter monitoring in predicting long-term efficacy and inefficacy of amiodarone used alone and in combination with class 1A antiarrhythmic agents in patients with ventricular tachycardia

AU - Kim, Soo G.

AU - Felder, S. D.

AU - Figura, I.

AU - Johnston, D. R.

AU - Waspe, L. E.

AU - Fisher, John Devens

PY - 1987

Y1 - 1987

N2 - The value of two reported and two new ambulatory electrocardiographic (Holter) criteria was studied in 80 patients taking amiodarone for refractory recurrent sustained ventricular tachycardia. In the 80 patients, the four Holter criteria were as follows: I - 85% or greater reduction of ventricular premature complexes and abolition of couplets and nonsustained ventricular tachycardia in 74 patients who had 10 or more ventricular premature complexes/h, or any couplets or nonsustained ventricular tachycardia/24 hours at baseline; II - abolition of nonsustained ventricular tachycardia in 51 patients who had nonsustained ventricular tachycardia at baseline; III - 85% or greater reduction of ventricular premature complexes and abolition of nonsustained ventricular tachycardia in 64 patients who had 30 or more ventricular premature complexes/h at baseline; and IV - 85% or greater reduction of ventricular premature complexes and abolition of nonsustained ventricular tachycardia in 73 patients who had 10 or more ventricular premature complexes/h at baseline. Amiodarone was judged effective in, respectively, 51 of 74, 44 of 51, 51 of 64, and 61 of 73 patients by criterion I, II, III or IV. During the follow-up period (19 ± 20 months), there were 19 instances of recurrences of ventricular arrhythmia or sudden death. Actuarial arrhythmia-free survival rate at 24 months was 84, 74, 86 and 85%, respectively, in patients with efficacy by criterion I, II, III or IV and 61, 43, 48 and 39%, respectively, in patients with inefficacy (p < 0.015 for all). Many patients with efficacy by Holter criteria, however, had a recurrence of arrhythmia, suggesting insensitivity of these Holter criteria. At 24 months, the respective sensitivity of criteria I, II, III and IV was 53, 29, 50 and 47%, the specificity was 86, 94, 90 and 95% and the predictive accuracy was 73, 63, 75, and 76%. Conclusions: 1) Inefficacy of amiodarone therapy by Holter criteria predicts a poor outcome but efficacy does not preclude a poor outcome (insensitivity). 2) Criterion I is the most sensitive but the least specific. 3) Criterion II could be used in only 51 of 80 patients and is the least sensitive. 4) Criterion III (with a stricter entry criterion) could be used in fewer patients than criterion I or IV and accuracy is not better. 5) Criterion IV is the most specific and has the best predictive accuracy. 6) Further studies should be done to identify the predictor of arrhythmia recurrence in patients with Holter criteria of efficacy.

AB - The value of two reported and two new ambulatory electrocardiographic (Holter) criteria was studied in 80 patients taking amiodarone for refractory recurrent sustained ventricular tachycardia. In the 80 patients, the four Holter criteria were as follows: I - 85% or greater reduction of ventricular premature complexes and abolition of couplets and nonsustained ventricular tachycardia in 74 patients who had 10 or more ventricular premature complexes/h, or any couplets or nonsustained ventricular tachycardia/24 hours at baseline; II - abolition of nonsustained ventricular tachycardia in 51 patients who had nonsustained ventricular tachycardia at baseline; III - 85% or greater reduction of ventricular premature complexes and abolition of nonsustained ventricular tachycardia in 64 patients who had 30 or more ventricular premature complexes/h at baseline; and IV - 85% or greater reduction of ventricular premature complexes and abolition of nonsustained ventricular tachycardia in 73 patients who had 10 or more ventricular premature complexes/h at baseline. Amiodarone was judged effective in, respectively, 51 of 74, 44 of 51, 51 of 64, and 61 of 73 patients by criterion I, II, III or IV. During the follow-up period (19 ± 20 months), there were 19 instances of recurrences of ventricular arrhythmia or sudden death. Actuarial arrhythmia-free survival rate at 24 months was 84, 74, 86 and 85%, respectively, in patients with efficacy by criterion I, II, III or IV and 61, 43, 48 and 39%, respectively, in patients with inefficacy (p < 0.015 for all). Many patients with efficacy by Holter criteria, however, had a recurrence of arrhythmia, suggesting insensitivity of these Holter criteria. At 24 months, the respective sensitivity of criteria I, II, III and IV was 53, 29, 50 and 47%, the specificity was 86, 94, 90 and 95% and the predictive accuracy was 73, 63, 75, and 76%. Conclusions: 1) Inefficacy of amiodarone therapy by Holter criteria predicts a poor outcome but efficacy does not preclude a poor outcome (insensitivity). 2) Criterion I is the most sensitive but the least specific. 3) Criterion II could be used in only 51 of 80 patients and is the least sensitive. 4) Criterion III (with a stricter entry criterion) could be used in fewer patients than criterion I or IV and accuracy is not better. 5) Criterion IV is the most specific and has the best predictive accuracy. 6) Further studies should be done to identify the predictor of arrhythmia recurrence in patients with Holter criteria of efficacy.

UR - http://www.scopus.com/inward/record.url?scp=0023067020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023067020&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 169

EP - 174

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 1

ER -